As on Thursday, Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) got off with the flyer as it spiked 3.48% to $17.84, before settling in for the price of $17.24 at the close. Taking a more long-term approach, CNTA posted a 52-week range of $7.38-$18.97.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
The Healthcare Sector giants’ yearly sales growth during the last 5-year period was 0.00%. Nevertheless, stock’s Earnings Per Share (EPS) this year is 2.97%. This publicly-traded company’s shares outstanding now amounts to $131.66 million, simultaneously with a float of $90.14 million. The organization now has a market capitalization sitting at $2.35 billion. At the time of writing, stock’s 50-day Moving Average stood at $16.83, while the 200-day Moving Average is $13.36.
Centessa Pharmaceuticals plc ADR (CNTA) Ownership Facts and Figures
Another important factor to analyze is how key investors are playing towards the stock of the Biotechnology industry. Centessa Pharmaceuticals plc ADR’s current insider ownership accounts for 31.53%, in contrast to 51.06% institutional ownership. According to the most recent insider trade that took place on Feb 03 ’25, this organization’s Chief People Officer sold 6,471 shares at the rate of 16.86, making the entire transaction reach 109,124 in total value, affecting insider ownership by 54,322. Preceding that transaction, on Feb 03 ’25, Company’s Chief Technology & Quality Ofc sold 11,000 for 16.86, making the whole transaction’s value amount to 185,406. This particular insider is now the holder of 121,503 in total.
Centessa Pharmaceuticals plc ADR (CNTA) Earnings and Revenue Records
Wall Street market experts anticipate that the next fiscal year will bring earnings of -0.37 per share during the current fiscal year.
Centessa Pharmaceuticals plc ADR’s EPS increase for this current 12-month fiscal period is 2.97% and is forecasted to reach -1.55 in the upcoming year.
Centessa Pharmaceuticals plc ADR (NASDAQ: CNTA) Trading Performance Indicators
Let’s observe the current performance indicators for Centessa Pharmaceuticals plc ADR (CNTA). It’s Quick Ratio in the last reported quarter now stands at 21.52. The Stock has managed to achieve an average true range (ATR) of 1.10. Another valuable indicator worth pondering is a publicly-traded company’s price to sales ratio for trailing twelve months, which is currently 339.92.
In the same vein, CNTA’s Diluted EPS (Earnings per Share) trailing twelve months is recorded -1.53, a figure that is expected to reach -0.42 in the next quarter, and analysts are predicting that it will be -1.55 at the market close of one year from today.
Technical Analysis of Centessa Pharmaceuticals plc ADR (CNTA)
Through scrutinizing the latest numbers posted by the [Centessa Pharmaceuticals plc ADR, CNTA], it can be observed that its last 5-days Average volume of 0.64 million was better the volume of 0.6 million, it posted the year before. During the previous 9 days, stock’s Stochastic %D was recorded 68.05% While, its Average True Range was 1.10.
Raw Stochastic average of Centessa Pharmaceuticals plc ADR (CNTA) in the period of the previous 100 days is set at 75.06%, which indicates a major fall in contrast to 91.28% during the last 2-weeks. If we go through the volatility metrics of the stock, In the past 14-days, Company’s historic volatility was 43.19% that was lower than 56.69% volatility it exhibited in the past 100-days period.
